Announcements Trials
Browse Landscape

Phase

Phase 3 2

Status

Completed 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 2

Conditions

Leukemia, Myeloid, Acute 24Breast Neoplasms 14Neoplasms 12Myelodysplastic Syndromes 12Prostatic Neoplasms 10Multiple Myeloma 8Lung Neoplasms 7Stomach Neoplasms 6Sarcoma 6Ovarian Neoplasms 5Leukemia, Myelomonocytic, Chronic 5Recurrence 4Neoplasm Metastasis 4Lymphoma, Non-Hodgkin 4Head and Neck Neoplasms 4Colorectal Neoplasms 4Carcinoma, Non-Small-Cell Lung 4Advanced Solid Tumor 4Uterine Cervical Neoplasms 3Squamous Cell Carcinoma of Head and Neck 3Solid Tumor 3Pain 3Mucositis 3Lymphoma, T-Cell, Peripheral 3Cholangiocarcinoma 3Carcinoma, Transitional Cell 3Carcinoma, Hepatocellular 3Stomatitis 2Small Cell Lung Carcinoma 2Skin Neoplasms 2

Interventions

Dexamethasone 5Magnetic Resonance Spectroscopy 4Cyclophosphamide 4Blood Specimen Collection 4Surveys and Questionnaires 3Prednisone 3Melphalan 3Lenalidomide 3Biopsy, Fine-Needle 3fluciclovine F-18 2carfilzomib 2Positron-Emission Tomography 2Mammography 2Injections 2Immunohistochemistry 2Gemcitabine 2Cytarabine 22-(3-(1-carboxy-5-((6-fluoropyridine-3-carbonyl)amino)pentyl)ureido)pentanedioic acid 2weifuchun 1vistusertib 1venetoclax 1technetium 99m 1-(1-(2-(bis(carboxymethyl)amino)-2-oxoethyl)-1H-imidazol-2-yl)-2-((1-(2-(bis(carboxymethyl)amino)-2-oxoethyl)-1H-imidazol-2-yl)methyl)-9,14-dioxo-2,8,13,15-tetraazaoctadecane-7,12,16,18-tetracarboxylic acid) 1ricolinostat 1pomalidomide 1phosphoribosylformylglycinamidine synthetase 1pembrolizumab 1ofatumumab 1obinutuzumab 1lortalamine 1irinotecan sucrosofate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Completed × Disease × Injections × Clear all
NCT04186845 2025-09-22

Spotlight

Blue Earth Diagnostics

Phase 3 Completed
391 enrolled 30 charts
Genitourinary

Disease, Prostatic Neoplasms

NCT04186819 2025-02-26

Imaging Study to Investigate the Safety and Diagnostic Performance of rhPSMA 7.3 (18F) in Newly Diagnosed Prostate Cancer.

Blue Earth Diagnostics

Phase 3 Completed
356 enrolled 28 charts
Genitourinary

Disease, Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡